Author(s): Francisco Cervantes, Heinz Gisslinger, Atanas Radinoff, et. al. EHA Library. Jun 15, 2019; 267082; PS1465 Session topic: 16. Myeloproliferative neoplasms – Clinical Abstract: PS1465 Background: RUX is the only approved JAK inhibitor for the treatment of disease-related splenomegaly or symptoms in adults with MF. Dose-dependent anemia has been observed with RUX,...
Pro zobrazení tohoto obsahu je třeba být přihlášen.